These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 26962696)
1. The Ocular Surface in Medically Controlled Glaucoma: An In Vivo Confocal Study. Villani E; Sacchi M; Magnani F; Nicodemo A; Williams SE; Rossi A; Ratiglia R; De Cillà S; Nucci P Invest Ophthalmol Vis Sci; 2016 Mar; 57(3):1003-10. PubMed ID: 26962696 [TBL] [Abstract][Full Text] [Related]
2. In vivo confocal microscopy of conjunctiva in preservative-free timolol 0.1% gel formulation therapy for glaucoma. Frezzotti P; Fogagnolo P; Haka G; Motolese I; Iester M; Bagaglia SA; Mittica P; Menicacci C; Rossetti L; Motolese E Acta Ophthalmol; 2014 Mar; 92(2):e133-40. PubMed ID: 24020826 [TBL] [Abstract][Full Text] [Related]
4. Symptoms and signs of tear film dysfunction in glaucomatous patients. Valente C; Iester M; Corsi E; Rolando M J Ocul Pharmacol Ther; 2011 Jun; 27(3):281-5. PubMed ID: 21557633 [TBL] [Abstract][Full Text] [Related]
5. An in vivo confocal microscopy analysis of effects of topical antiglaucoma therapy with preservative on corneal innervation and morphology. Martone G; Frezzotti P; Tosi GM; Traversi C; Mittica V; Malandrini A; Pichierri P; Balestrazzi A; Motolese PA; Motolese I; Motolese E Am J Ophthalmol; 2009 Apr; 147(4):725-735.e1. PubMed ID: 19181302 [TBL] [Abstract][Full Text] [Related]
6. Tear film osmolarity in patients treated for glaucoma or ocular hypertension. Labbé A; Terry O; Brasnu E; Van Went C; Baudouin C Cornea; 2012 Sep; 31(9):994-9. PubMed ID: 22710490 [TBL] [Abstract][Full Text] [Related]
7. Corneoscleral limbus in glaucoma patients: in vivo confocal microscopy and immunocytological study. Mastropasqua R; Agnifili L; Fasanella V; Curcio C; Brescia L; Lanzini M; Fresina M; Mastropasqua L; Marchini G Invest Ophthalmol Vis Sci; 2015 Mar; 56(3):2050-8. PubMed ID: 25744981 [TBL] [Abstract][Full Text] [Related]
8. [Corneal sensitivity in patients treated medically for glaucoma or ocular hypertension]. Van Went C; Alalwani H; Brasnu E; Pham J; Hamard P; Baudouin C; Labbé A J Fr Ophtalmol; 2011 Dec; 34(10):684-90. PubMed ID: 22093372 [TBL] [Abstract][Full Text] [Related]
9. Ocular Surface Disease in Patients under Topical Treatment for Glaucoma. Pérez-Bartolomé F; Martínez-de-la-Casa JM; Arriola-Villalobos P; Fernández-Pérez C; Polo V; García-Feijoó J Eur J Ophthalmol; 2017 Nov; 27(6):694-704. PubMed ID: 28497458 [TBL] [Abstract][Full Text] [Related]
10. Ocular Surface Disease in Glaucoma: Effect of Polypharmacy and Preservatives. Ramli N; Supramaniam G; Samsudin A; Juana A; Zahari M; Choo MM Optom Vis Sci; 2015 Sep; 92(9):e222-6. PubMed ID: 25730335 [TBL] [Abstract][Full Text] [Related]
11. Assessment of Corneal Changes Associated with Topical Antiglaucoma Therapy Using in vivo Confocal Microscopy. Baghdasaryan E; Tepelus TC; Vickers LA; Huang P; Chopra V; Sadda SR; Lee OL Ophthalmic Res; 2019; 61(1):51-59. PubMed ID: 29627838 [TBL] [Abstract][Full Text] [Related]
12. Sodium hyaluronate decreases ocular surface toxicity induced by benzalkonium chloride-preserved latanoprost: an in vivo study. Yu F; Liu X; Zhong Y; Guo X; Li M; Mao Z; Xiao H; Yang S Invest Ophthalmol Vis Sci; 2013 May; 54(5):3385-93. PubMed ID: 23620425 [TBL] [Abstract][Full Text] [Related]
13. Long-term effect of BAK-free travoprost on ocular surface and intraocular pressure in glaucoma patients after transition from latanoprost. Aihara M; Otani S; Kozaki J; Unoki K; Takeuchi M; Minami K; Miyata K J Glaucoma; 2012 Jan; 21(1):60-4. PubMed ID: 21278589 [TBL] [Abstract][Full Text] [Related]
14. Ocular surface tolerability of prostaglandin analogs in patients with glaucoma or ocular hypertension. Whitson JT; Trattler WB; Matossian C; Williams J; Hollander DA J Ocul Pharmacol Ther; 2010 Jun; 26(3):287-92. PubMed ID: 20578283 [TBL] [Abstract][Full Text] [Related]
15. Clinical audit examining the impact of benzalkonium chloride-free anti-glaucoma medications on patients with symptoms of ocular surface disease. Goldberg I; Graham SL; Crowston JG; d'Mellow G; Clin Exp Ophthalmol; 2015 Apr; 43(3):214-20. PubMed ID: 25196488 [TBL] [Abstract][Full Text] [Related]
16. Confocal microscopy of epithelial and langerhans cells of the cornea in patients using travoprost drops containing two different preservatives. Marsovszky L; Resch MD; Visontai Z; Németh J Pathol Oncol Res; 2014 Jul; 20(3):741-6. PubMed ID: 24623372 [TBL] [Abstract][Full Text] [Related]
17. Vitamin A Palmitate and Carbomer Gel Protects the Conjunctiva of Patients With Long-term Prostaglandin Analogs Application. Cui X; Xiang J; Zhu W; Wei A; Le Q; Xu J; Zhou X J Glaucoma; 2016 Jun; 25(6):487-92. PubMed ID: 26317483 [TBL] [Abstract][Full Text] [Related]
18. Ocular Redness Measured with the Keratograph 5M in Patients Using Anti-Glaucoma Eye Drops. Pérez Bartolomé F; Martínez de la Casa JM; Arriola Villalobos P; Fernández Pérez C; Polo V; Sánchez Jean R; García Feijoó J Semin Ophthalmol; 2018; 33(5):643-650. PubMed ID: 29144869 [TBL] [Abstract][Full Text] [Related]
19. DI Staso S; Agnifili L; Ciancaglini M; Murano G; Borrelli E; Mastropasqua L In Vivo; 2018; 32(2):437-443. PubMed ID: 29475934 [TBL] [Abstract][Full Text] [Related]
20. Effect of Switching to Travoprost Preserved With SofZia in Glaucoma Patients With Chronic Superficial Punctate Keratitis While Receiving BAK-preserved Latanoprost. Aihara M; Ikeda Y; Mizoue S; Arakaki Y; Kita N; Kobayashi S; J Glaucoma; 2016 Jun; 25(6):e610-4. PubMed ID: 25967526 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]